Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO clinical practice guidelines for use

Annals of Oncology

Volumn 21, Issue SUPPL. 5, 2010, Pages

  Schrijvers, D ^a   de Samblanx, H ^a   Roila, F ^b  

^a ZiekenhuisNetwerk Antwerpen   (Belgium)

^b S MARIA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT; C REACTIVE PROTEIN; CORTICOSTEROID; CYANOCOBALAMIN; DOXORUBICIN; FERRITIN; FOLIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; IRON; LENALIDOMIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; THALIDOMIDE; TRANSFERRIN;

ANEMIA; ARTHRALGIA; ARTICLE; AUTOIMMUNE DISEASE; BLOOD ANALYSIS; BLOOD SMEAR; BONE MARROW TRANSPLANTATION; CANCER RADIOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COOMBS TEST; DISEASE FREE SURVIVAL; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ERYTHROCYTE COUNT; EUROPE; HEMATOCRIT; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERTENSION; INJECTION SITE PAIN; LIVER DYSFUNCTION; MALIGNANT NEOPLASTIC DISEASE; MEDICAL ASSESSMENT; MEDICAL SOCIETY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; OCCULT BLOOD; OFF LABEL DRUG USE; OVERALL SURVIVAL; PERIPHERAL EDEMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PURE RED CELL ANEMIA; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RASH; RETICULOCYTE COUNT; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; URINALYSIS; URTICARIA;

EID: 77954319713     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq202     Document Type: Article

References (24)

1. Blanc B, Finch CA, Hallberg L et al. Nutritional anaemias. Report of a WHO Scientific Group. WHO Tech Rep Ser 1968, 405: 1-40
2. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999, 91: 1616-1634
3. Mercadante S, Gebbia V, Marrazzo A et al. Anemia in cancer: pathophysiology and treatment. Cancer Treat Rev 2000, 26: 303-311
4. Wilson J, Yao GL, Raftery J et al. A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess 2007, 11: 1-202
5. Ludwig H, Van Belle S, Barrett-Lee et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004, 40: 2293-2306
6. Jabbour E, Kantarjian HM, Koller C, Taher A. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes. Cancer 2008, 112: 1089-1095
7. Birgegård G, Gascón P, Ludwig H. Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European Cander Anaemia Survey. Eur J Haematol 2006, 77: 378-386
8. http://ctep.info.nih.gov/reporting/ctc_archive.html (last accessed 8 May 2009)
9. Harper P, Littlewood T. Anaemia of cancer: impact on patient fatigue and long-term outcome. Oncology 2005, 69 (Suppl 2): 2-7
10. Ryan JL, Carroll JK, Ryan EP et al. Mechanisms of cancer-related fatigue. Oncologist 2007, 12 (Suppl 1): 22-34
11. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systematic, quantitative review. Cancer 2001, 91: 2214-2221
12. http://www.emea.europa.eu/humandocs/Humans/EPAR (last accessed 17 March 2008)
13. Bohlius J, Wilson J, Seidenfeld J et al. Erythropoetin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2006, issue 3: CD003407
14. Glaspy JA. Erythropoietin in cancer patients. Annu Rev Med 2009, 60: 181-192
15. Casadevall N, Durieux P, Dubois S et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood 2004, 104: 321-327
16. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Br J Haematol 1998, 103: 1070-1074
17. Ross SD, Allen IE, Probst CA et al. Efficacy and safety of erythropoiesis-stimulating proteins in myelodysplastic syndrome: a systematic review and meta-analysis. Oncologist 2007, 12: 1264-1273
18. Auerbach M, Ballard H, Trout JR et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004, 22: 1301-1307
19. Bastit L, Vandebroek A, Altintas S et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 2008, 26: 1611-1618
20. Smith RE, Aapro M, Ludwig H et al. Darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 2008, 26: 1040-1050
21. Ludwig H, Crawford J, Osterborg A et al. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol 2009, 27: 2838-2847
22. Bohlius J, Schmidlin K, Brillant C et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009, 373: 1532-1542. Erratum in Lancet 2009; 374: 28
23. Tonelli M, Hemmelgarn B, Reiman T et al. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ 2009, 180: E62-E71
24. Bennett CL, Luminari S, Nissenson AR et al. Pure red cell aplasia and epoetin therapy. N Engl J Med 2004, 351: 1403-1408